DKK1 and neoplasm: DKK1 has since been shown to increase tumor growth and support an immunosuppressive environment by signaling to MDSCs, and treatment with a DKK1 neutralizing antibody, DKN, 01, was able to mitigate tumor growth by reduced levels of MDSCs and increased entry of effector T cells into the TME [127, 128].